Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL

This study is testing orelabrutinib — a targeted oral therapy that blocks a cancer-driving protein — as a treatment for early-stage (stage I or II) marginal zone lymphoma (MZL), a slow-growing type of non-Hodgkin lymphoma that has not been treated before. **You may be eligible if...** - You are 18 or older - You have been confirmed to have stage I or II marginal zone lymphoma by biopsy - You have not yet received treatment for this lymphoma - Your general health is good enough to carry out daily activities (ECOG 0–2) - Your blood counts, liver, and kidney function are within acceptable ranges - Your expected survival is at least 12 months **You may NOT be eligible if...** - Your lymphoma has spread to the brain or transformed into a more aggressive type - You have significant heart problems (heart failure, recent heart attack, or dangerous heart rhythms) - You have had active bleeding in the last 2 months or are currently on blood thinners - You have poorly controlled high blood pressure despite multiple medications - You have a history of clinically meaningful irregular heart rhythms (prolonged QT interval) Talk to your doctor to see if this trial is right for you.